Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mucinous colorectal adenocarcinoma

ABSTRACT: Mucinous colorectal adenocarcinoma

PROVIDER: PRJNA992109 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR25170137_1.fastq.gz	Fastqsanger.gz
	SRR25170137_2.fastq.gz	Fastqsanger.gz
	SRR25170138_1.fastq.gz	Fastqsanger.gz
	SRR25170138_2.fastq.gz	Fastqsanger.gz
	SRR25170139_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 76

Similar Datasets

Spatial transcriptomics reveals functional compartmentalization of mucinous colorectal adenocarcinoma

Project description:Spatial transcriptomics reveals functional compartmentalization of mucinous colorectal adenocarcinoma

| PRJNA992207 | ENA

Spatial transcriptomics reveals functional compartmentalization of mucinous colorectal adenocarcinoma

Project description:We performed spatial transcriptomics to profile compositional and spatial distribution of hetergeneous cell populations in mucinous colorectal adenocarinoma

2024-04-28 | GSE236697 | GEO

Proteome profiling of mucinous and non-mucinous colorectal cancer

Project description:Mucus is associated with poor prognosis of colorectal cancer, but its mechanism remains unclear. The aim of this study was to reveal the key proteins in mucinous colorectal cancer. In this study, high-resolution liquid chromatography tandem mass spectrometry (LC-MS / MS) combined with quantitative 6-plex tandem mass mass tag labeling was used to profile protein changes in the left and right sides of mucinous and non-mucinous colorectal cancer tissues. A total of 7432 proteins were identified and analyzed.

2020-11-28 | PXD022802 |

Gene signature driving invasive mucinous adenocarcinoma of the lung

Project description:Gene signature driving invasive mucinous adenocarcinoma of the lung

| PRJNA343081 | ENA

A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC)

Project description:This is an open-label, single center, non-randomized, phase Ⅱ trial to evaluate safety and efficacy of using the combination treatment of Camrelizumab with anti-angiogenic drugs and Chemotherapy of metastatic colorectal mucinous adenocarcinoma(MAC).

| 2343664 | ecrin-mdr-crc

SNP arrays in colorectal adenocarcinoma cell lines

Project description:SNP arrays in colorectal adenocarcinoma cell lines

2024-06-05 | GSE267025 | GEO

Identification of a gene expression signature in colorectal adenocarcinoma in comparison with colorectal adenoma

Project description:We showed that a lot of genes were deregulated in colorectal adenocarcinomas in comparison with colorectal adenomas. 37 colorectal adenoma and 9 colorectal adenocarcinoma samples were analyzed. We generated a comparison between adenocarcinomas and adenomas.

2013-08-27 | E-GEOD-50115 | biostudies-arrayexpress

Mucinous colorectal adenocarcinoma

Project description:This SuperSeries is composed of the SubSeries listed below.

2024-04-28 | GSE236698 | GEO

LSD1 and CoREST2 Regulate STAT3 Activity to Promote Enteroendocrine Cell Differentiation in Mucinous Colorectal Cancer[scMultiome-seq]

Project description:Neuroendocrine cells have been implicated in therapeutic resistance and worse overall survival in many cancer types. Mucinous colorectal cancer (mCRC) is uniquely enriched for enteroendocrine cells (EECs), the neuroendocrine cell of the normal colon epithelium, as compared to non-mucinous CRC. Therefore, targeting EEC differentiation may have clinical value in mCRC. Here, single cell multi-omics was used to uncover epigenetic alterations that accompany EEC differentiation, identify STAT3 as a novel regulator of EEC specification, and discover a rare cancer-specific cell type with enteric neuron-like characteristics. Further experiments demonstrated that lysine-specific demethylase 1 (LSD1) and CoREST2 mediate STAT3 demethylation and regulate STAT3 chromatin binding. Knockdown of CoREST2 in an orthotopic xenograft mouse model resulted in decreased primary tumor growth and lung metastases. In culmination, these results provide rationale for new LSD1 inhibitors that target the interaction between LSD1 with STAT3 or CoREST2, which may improve clinical outcomes for patients with mCRC.

2024-09-19 | GSE268957 | GEO

LSD1 and CoREST2 Regulate STAT3 Activity to Promote Enteroendocrine Cell Differentiation in Mucinous Colorectal Cancer[CUT&RUN]

2024-09-19 | GSE268956 | GEO